Thermo Fisher Scientific Inc

TMO is in a Stage 2 advancing regime supported by an active Lockout Rally driving forced participation. Despite extreme overbought conditions, price stacking above the rising 9/21/50 EMAs and institutional demand dynamics support further upside continuation; we will engage immediately on continuation structures, aligning with shallow EMA pullbacks.

• ↑Q1 revenue $11.01 B (+6% YoY) with adjusted EPS $5.44 (+6%).
• ↑Clario deal to contribute ~$0.45 EPS first year, boosting clinical research exposure.
• ↓Academic/government segment revenue fell low single digits, dragging growth.